Hope for non-responders with hepatitis C virus and cirrhosis

The Lancet Infectious Diseases

Volumn 15, Issue 4, 2015, Pages 363-365

  Dusheiko, Geoffrey ^a   MacDonald, Douglas ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; END STAGE LIVER DISEASE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; INNATE IMMUNITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MODEL FOR END STAGE LIVER DISEASE SCORE; NATURAL KILLER CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; TREATMENT RESPONSE; FEMALE; MALE;

FEMALE; HUMANS; MALE;

EID: 84925371856     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70094-0     Document Type: Note

References (12)

1. Westbrook RH, Dusheiko G Natural history of hepatitis C. J Hepatol 2014, 61(1 suppl):S58-S68.
2. Bourlière M, Bronowicki J-P, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV hepatitis C virus genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015, published online March 13. http://dx.doi.org/10.1016/S1473-3099(15)70050-2.
3. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014, 370:1973-1982.
4. Muir A, Poordad F, Lalezari J All oral fixed dose combination with daclatasvir asunaprevir and BMS 791325 plus or minus ribavirin for patients with chronic hepatitis C genotype 1 infection and compensated cirrhosis: Unity -2 phase 3 SVR12 results. Hepatoloogy 2014, 60(suppl):LB2.
5. Werner JM, Serti E, Chepa-Lotrea X, et al. Ribavirin improves the IFN-g response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology 2014, 60:1160-1169.
6. Mondelli MU The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?. Hepatology 2014, 60:1126-1129.
7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
8. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014, 147:132-142. e4.
9. Van Der Meer AJ, Hansen BE, Fattovich G, et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut 2015, 64:322-331.
10. Sulkowski M, Mallolas J, Bourliere M, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014, published online Nov 11. http://dx.doi.org/10.1016/S0140-6736(14)61793-1.
11. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014, published online Nov 11. http://dx.doi.org/10.1016/S0140-6736(14)61795-5.
12. Van Der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308:2584-2593.